Description

This Computer Simulation Assessment Tool (CSAT) helps you effectively assess and treat patients who have irritable depression.

In order to provide optimal care, it is critical for mental health professionals to identify mixed features in patients who present with depression. They are at risk for other conditions such as bipolar disorder, substance use disorders, suicidality and more.

During this activity, view a simulated clinical encounter with a patient and make clinical decisions on assessment and treatment. Review patient information and video vignettes, and choose from a menu of treatment and discussion options that mirror the choices you typically face in actual clinical encounter. Plus, receive feedback on your performance relative to your peers.

Learning Objectives

At the end of this educational activity, participants should be able to:

  • Assess patients with depression for subsyndromal mixed features.
  • Differentiate between different causes of irritability in depression, such as mixed features, anxiety, substance abuse, and ADHD.
  • Suggest an appropriate treatment plan for a patient with irritable depression.

Target Audience

Psychiatrists, psychologists, primary care/family physicians, nurses and nurse practitioners, and allied healthcare professionals.

Faculty

  • Thomas P. Hackett, MD, Endowed Chair in Psychiatry at MGH,
    Director, Bipolar Clinic and Research Program,
    Associate Director, Depression Clinical and Research Program,
    Director, Training and Education, MGH Research Institute,
    Massachusetts General Hospital,
    Professor of Psychiatry, Harvard Medical School

Educational Support

This program has received support in the form of educational grants from Janssen Global Services, LLC, Sunovion Pharmaceuticals, Inc., and Takeda Pharmaceuticals International, Inc.

Computer Simulation Assessment Tools

We offer several free Computer Simulation Assessment Tools. See the full list at the link below.

View our online computer simulation assessment tools course offerings

CME Information

Release Date: December 30, 2015
Expiration Date: December 30, 2017
Review Date: December 20, 2016 by Robert Althoff, MD


CREDIT

TYPE

ACCREDITATION STATEMENT

DESIGNATION STATEMENT

1

AMA PRA Category 1 CreditTM

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of McLean Hospital and Massachusetts General Hospital. McLean Hospital is accredited by the ACCME to provide continuing medical education for physicians.

McLean Hospital designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

1

Psychologists CE Credit

The Massachusetts General Hospital Department of Psychiatry is approved by the American Psychological Association to sponsor continuing education for psychologists. The Massachusetts General Hospital Department of Psychiatry maintains responsibility for this program and its content.

This offering meets the criteria for 1 continuing education credit for psychologists.

1

Nursing Contact Hours

Massachusetts General Laws, Chapter 13, sections 13, 14, 14A, 15 and 15D and Chapter 112, sections 74 through 81C authorize the Board of Registration in Nursing to regulate nursing practice and education.

This program meets the requirements of the Massachusetts Board of Registration in Nursing at (244 CMR 5.00) for 1 contact hours of nursing continuing education credit.

1

(self-claim)

Other Professions

Other Providers can claim a Participation Certificate upon successful completion of this course.

Participation Certificates will specify the title, location, type of activity, date of activity, and number of AMA PRA Category 1 CreditsTM associated with the activity. Providers should check with their regulatory agencies to determine ways in which AMA PRA Category 1 CreditsTM may or may not fulfill continuing education requirements. Providers should also consider saving copies of brochures, agenda, and other supporting documents.


Policy on Faculty and Provider Disclosure

It is the policy of McLean Hospital that faculty and providers disclose real or apparent conflicts of interest relating to the topics of this educational activity. McLean Hospital has established policies in place that identify and resolve all conflicts of interest prior to this educational activity.

Planner Disclosures

The following planners and/or their spouse/partner have reported no relevant financial relationship with a commercial interest:

David H. Rubin, MD, Reviewer
Jane Pimental, MPH

The following planners and/or their spouse/partner have reported a relevant financial relationship with a commercial interest:

Michael Hirsch, MD
Royalties: UpToDate

Susan E. Sprich, PhD
Royalties: Oxford University Press (for co-authoring treatment manual and client workbook), Springer (for editing book)


Speaker Disclosures

The following speakers and/or their spouse/partner have reported no relevant financial relationship with a commercial interest:

Mark Soucy, role play actor
Jane Lanier, MD, role play actor

The following speakers and/or their spouse/partner have reported a relevant financial relationship with a commercial interest:

Andrew A. Nierenberg, MD

Consultant: Abbott Laboratories, American Psychiatric Association, Appliance Computing Inc. Mindsite , Basliea, Brain Cells, Inc., Brandeis University, Bristol Myers Squibb, Clintara, Corcept, Dey Pharmaceuticals, Dainippon Sumitomo now Sunovion , Eli Lilly and Company, EpiQ, L.P./Mylan Inc., Forest, Genaissance, Genentech, GlaxoSmithKline, Healthcare Global Village, Hoffman LaRoche, Infomedic, Lundbeck, Janssen Pharmaceutica, Jazz Pharmaceuticals, Medavante, Merck, Methylation Sciences, Naurex, Novartis, PamLabs, Parexel, Pfizer, PGx Health, Otsuka, Ridge Diagnostics Shire, Schering-Plough, Somerset, Sunovion, Takeda Pharmaceuticals, Targacept, and Teva; consulted through the MGH Clinical Trials Network and Institute CTNI for Astra Zeneca, Brain Cells, Inc, Dianippon Sumitomo/Sepracor, Johnson and Johnson, Labopharm, Merck, Methylation Science, Novartis, PGx Health, Shire, Schering-Plough, Targacept and Takeda/Lundbeck Pharmaceuticals

Grants/Research Support: American Foundation for Suicide Prevention, AHRQ, Brain and Behavior Research Foundation, Bristol-Myers Squibb, Cederroth, Cephalon, Cyberonics, Elan, Eli Lilly, Forest, GlaxoSmithKline, Janssen Pharmaceutica, Lichtwer Pharma, Marriott Foundation, Mylan, NIMH, PamLabs, PCORI, Pfizer Pharmaceuticals, Shire, Stanley Foundation, Takeda, and Wyeth-Ayerst

Honoraria: Belvoir Publishing, University of Texas Southwestern Dallas, Brandeis University, Bristol-Myers Squibb, Hillside Hospital, American Drug Utilization Review, American Society for Clinical Psychopharmacology, Baystate Medical Center, Columbia University, CRICO, Dartmouth Medical School, Health New England, Harold Grinspoon Charitable Foundation, IMEDEX, International Society for Bipolar Disorder, Israel Society for Biological Psychiatry, Johns Hopkins University, MJ Consulting, New York State, Medscape, MBL Publishing, National Association of Continuing Education, Physicians Postgraduate Press, SUNY Buffalo, University of Wisconsin, University of Pisa, University of Michigan, University of Miami, University of Wisconsin at Madison, APSARD, ISBD, SciMed, Slack Publishing and Wolters Klower Publishing, ASCP, NCDEU, Rush Medical College, Yale University School of Medicine, NNDC, Nova Southeastern University, NAMI, Institute of Medicine, CME Institute, ISCTM, World Congress on Brain Behavior and Emotion, Congress of the Hellenic Society for Basic and Clinical Pharmacology, ADAA

Stock: Appliance Computing, Inc. MindSite ; Brain Cells, Inc., Medavante

Copyrights: Clinical Positive Affect Scale and the MGH Structured Clinical Interview for the Montgomery Asberg Depression Scale exclusively licensed to the MGH Clinical Trials Network and Institute CTNI

Educational Support

This program has received support in the form of educational grants from Janssen Global Services, LLC, Sunovion Pharmaceuticals, Inc., and Takeda Pharmaceuticals International, Inc.